Biotechnology company Synaffix has announced it has entered a licensing agreement with biopharmaceutical company Qurient Therapeutics for the development of a dual-payload antibody-drug conjugates (ADCs).  Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enhance therapeutic efficacy and mitigate payload resistance. Their therapeutic […]